Home Industries Market Insights About Us Publisher Contact us

Anti-Obesity Therapeutics Market Size, Share & Trends Analysis Report By Mechanism of Action (Peripherally acting anti-obesity drugs, Centrally acting anti-obesity drugs), By Type (Prescription Drugs (Rx), OTC Drugs), By Medication (Monotherapies, Polytherapies), Region (North America, Europe, Asia-Pacific, Middle East & Africa, and South America)—Forecast till 2028

Categories: Life Science

Formate :


Global Anti-Obesity Therapeutics Market Overview

The Global Anti-Obesity Therapeutics Market size is estimated to reach $10.1 Billion by 2026, growing at a CAGR of 16.8% over the forecast period of 2021-2026.

Anti-obesity therapies are medications that help people lose or maintain their weight. These drugs affect one of the body's most basic functions, weight management, by affecting appetite or calorie absorption. Dieting and physical activity remain the primary therapeutic strategies for overweight and obese people.

Because the effectiveness of these anti-obesity medications is restricted to maintaining the same weight rather than acting as an antidote, essential therapies such as limiting the consumption of unhealthy foods and instilling exercise as a part of daily routine exist.

Obesity is on the rise, owing to a lack of sleep, lack of physical activity, and a high-calorie diet, as well as heredity and family history. Obesity can also be caused by taking certain medications.

 

COVID 19 Impacts:

The COVID-19 pandemic has impacted every industry sector across the world. Research Informatic are constantly apprehending the influence of the COVID-19 pandemic on different domains of the industry. Our research reports provide comprehensive research of COVID-19, which will guide you to understand the significant growth driving and restraining factors. Furthermore, the Global Anti-Obesity Therapeutics research report helps you with the statistics, revised government policies, and many other valuable understandings.

 

Key Takeaways from Global Anti-Obesity Therapeutics Market Report:

  • Evaluate market potential through analyzing growth rates (CAGR %), Volume (Units), and Value ($M) data given at country level – for the mechanism of Action, Type, Medication, and by different industry verticals.
  • Understand the different market dynamics – key driving factors, challenges, and hidden opportunities.
  • Get in-depth insights on your competitor's performance – market shares, strategies, financial benchmarking, product benchmarking, SWOT, and more.
  • Analyze the sales and distribution channels across key geographies to improve top-line revenues.
  • Understand the industry supply chain with a deep dive on the value augmentation at each step to optimize value and bring efficiencies in your processes.
  • Get a quick outlook on the market entropy – M&As, deals, partnerships, product launches of all key players for the past 4 years.
  • Evaluate the supply-demand gaps, import-export statistics, and regulatory landscape for more than the top 20 countries globally for the market.

 

Market Dynamics

Driver: Increasing number of Bariatric Surgery drives the market demand

Previously, bariatric surgery/weight loss surgery was thought to be the final resort for weight loss when diets, exercise, and other medically advised regimens had failed. On the other hand, bariatric operations have become less unpleasant for patients as a result of technical developments.

As a result, the medical profession increasingly accepts these operations as a viable and long-lasting alternative to traditional weight-loss methods. This aspect, combined with rising obesity rates, has resulted in a jump in the number of bariatric procedures performed worldwide. This factor is driving the growth of the Anti-Obesity Therapeutics Market.

 

Challenge: Low treatment rate for the illness limits market growth.

Even though the worldwide obesity population is increasing, a lack of effective weight management education and people's incorrect attitudes are two reasons contributing to the disorder's lower treatment rate.

In addition, only 2% of the obese population is treated with prescription drugs, according to IQVIA. This is a crucial factor in decreased medication uptake, limiting the market growth.

 

By Mechanism of Action, the Peripherally Acting Anti-Obesity Drugs market is estimated to grow at the highest CAGR during the forecast period.

Based on Nature, the Global Anti-Obesity Therapeutics Market is segmented into Peripherally Acting Anti-Obesity Drugs, Centrally Acting Drugs. Centrally Acting Drugs dominated the Anti-Obesity Therapeutics Market in 2020. This is due to most sales being encountered for Centrally Acting Drugs in 2020.

However, Peripherally Acting Anti-Obesity Drugs is the fastest growing over the period 2021-2026 with a CAGR of 17.3%. This is due to the increasing demand for peripherally Acting Anti-Obesity Drugs that reduce calorie absorption in the gastrointestinal tract or impact metabolic and/or control systems outside the central nervous system to moderate their effects (CNS).

 

Geographical Overview

The Asia Pacific to account for the largest market share during the forecast period

North America dominated the Global Anti-Obesity Therapeutics Market with a share of 37.9% in 2020. This is due to the increasing obesity population in the United States driving the demand in North America. Furthermore, the growing dominance of anti-obesity treatment with high usage of obesity management products led to a significant share of the Anti-Obesity Therapeutics Market in North America.

 

However, Asia Pacific is the fastest-growing over 2021-2026. The rise in disposable income, increase in the number of diabetics, greater awareness of personal well-being, sedentary lifestyles, and the inexpensive cost of bariatric procedures in this region contribute to this trend.

Key Market Players:

Key Players in the Global Anti-Obesity Therapeutics Market consist of Bristol-Myers Squibb, Eisai Company, GlaxoSmithKline plc, Novo Nordisk, Alizyme, Boehringer Ingelheim GmbH, Pfizer, Takeda Pharmaceutical, Rhythm Pharmaceuticals, Shionogi USA, Vivus, Zafgen, and Norgine Pharmaceuticals Ltd. among others.

 

Recent Developments:

In January 2021, Novartis AG's Phase II study findings of the experimental medication Bimagrumab were released. The medication has shown promise in the treatment of obesity. The medication is now being investigated by Novartis.

 

Report Coverage and Scope

The report "Global Anti-Obesity Therapeutics Market" by Research Informatic covers an in-depth detailed analysis for the following segment, covered under the scope.

 

By Mechanism of Action

  • Peripherally acting anti-obesity drugs
  • Centrally acting anti-obesity drugs

 

By Type

 

  • Prescription Drugs (Rx)
  • OTC Drugs

 

By Medication

 

  • Monotherapies
  • Polytherapies

 

Geography

 

  • North America
  • Europe
  • APAC
  • RoW

 

SWOT analysis:

The report is created based on comprehensive SWOT analysis and Porter's five force analysis tools; the strengths, weaknesses, opportunities, and combinations of key companies are extensively figured out in the report. Furthermore, every prominent player in the global market is outlined with their associated details such as product types, market overview, marketing strategies, production base, applications, and other specifications.

 

 

 


Global Anti-Obesity Therapeutics Market Growth, Trend and Forecast 2021-2028

Chapter 1 Anti-Obesity Therapeutics Market Overview
1.1 Product Overview and Scope of Anti-Obesity Therapeutics
1.2 Anti-Obesity Therapeutics Market Segmentation by Type
1.2.1 Global Production Market Share of Anti-Obesity Therapeutics by Type in 2020
1.2.1 Type 1
1.2.2 Type 2
1.2.3 Type 3
1.3 Anti-Obesity Therapeutics Market Segmentation by Application
1.3.1 Anti-Obesity Therapeutics Consumption Market Share by Application in 2020
1.3.2 Application 1
1.3.3 Application 2
1.3.4 Application 3
1.4 Anti-Obesity Therapeutics Market Segmentation by Regions
1.4.1 North America
1.4.2 China
1.4.3 Europe
1.4.4 Southeast Asia
1.4.5 Japan
1.4.6 India
1.5 Global Market Size (Value) of Anti-Obesity Therapeutics (2014-2028)

Chapter 2 Global Economic Impact on Anti-Obesity Therapeutics Industry
2.1 Global Macroeconomic Environment Analysis
2.1.1 Global Macroeconomic Analysis
2.1.2 Global Macroeconomic Environment Development Trend
2.2 Global Macroeconomic Environment Analysis by Regions

Chapter 3 Global Anti-Obesity Therapeutics Market Competition by Manufacturers
3.1 Global Anti-Obesity Therapeutics Production and Share by Manufacturers (2020 and 2020)
3.2 Global Anti-Obesity Therapeutics Revenue and Share by Manufacturers (2020 and 2020)
3.3 Global Anti-Obesity Therapeutics Average Price by Manufacturers (2020 and 2020)
3.4 Manufacturers Anti-Obesity Therapeutics Manufacturing Base Distribution, Production Area and Product Type
3.5 Anti-Obesity Therapeutics Market Competitive Situation and Trends
3.5.1 Anti-Obesity Therapeutics Market Concentration Rate
3.5.2 Anti-Obesity Therapeutics Market Share of Top 3 and Top 5 Manufacturers
3.5.3 Mergers & Acquisitions, Expansion

Chapter 4 Global Anti-Obesity Therapeutics Production, Revenue (Value) by Region (2014-2021)
4.1 Global Anti-Obesity Therapeutics Production by Region (2014-2021)
4.2 Global Anti-Obesity Therapeutics Production Market Share by Region (2014-2021)
4.3 Global Anti-Obesity Therapeutics Revenue (Value) and Market Share by Region (2014-2021)
4.4 Global Anti-Obesity Therapeutics Production, Revenue, Price and Gross Margin (2014-2021)
4.5 North America Anti-Obesity Therapeutics Production, Revenue, Price and Gross Margin (2014-2021)
4.6 Europe Anti-Obesity Therapeutics Production, Revenue, Price and Gross Margin (2014-2021)
4.7 China Anti-Obesity Therapeutics Production, Revenue, Price and Gross Margin (2014-2021)
4.8 Japan Anti-Obesity Therapeutics Production, Revenue, Price and Gross Margin (2014-2021)
4.9 Southeast Asia Anti-Obesity Therapeutics Production, Revenue, Price and Gross Margin (2014-2021)
4.10 India Anti-Obesity Therapeutics Production, Revenue, Price and Gross Margin (2014-2021)

Chapter 5 Global Anti-Obesity Therapeutics Supply (Production), Consumption, Export, Import by Regions (2014-2021)
5.1 Global Anti-Obesity Therapeutics Consumption by Regions (2014-2021)
5.2 North America Anti-Obesity Therapeutics Production, Consumption, Export, Import by Regions (2014-2021)
5.3 Europe Anti-Obesity Therapeutics Production, Consumption, Export, Import by Regions (2014-2021)
5.4 China Anti-Obesity Therapeutics Production, Consumption, Export, Import by Regions (2014-2021)
5.5 Japan Anti-Obesity Therapeutics Production, Consumption, Export, Import by Regions (2014-2021)
5.6 Southeast Asia Anti-Obesity Therapeutics Production, Consumption, Export, Import by Regions (2014-2021)
5.7 India Anti-Obesity Therapeutics Production, Consumption, Export, Import by Regions (2014-2021)

Chapter 6 Global Anti-Obesity Therapeutics Production, Revenue (Value), Price Trend by Type
6.1 Global Anti-Obesity Therapeutics Production and Market Share by Type (2014-2021)
6.2 Global Anti-Obesity Therapeutics Revenue and Market Share by Type (2014-2021)
6.3 Global Anti-Obesity Therapeutics Price by Type (2014-2021)
6.4 Global Anti-Obesity Therapeutics Production Growth by Type (2014-2021)

Chapter 7 Global Anti-Obesity Therapeutics Market Analysis by Application
7.1 Global Anti-Obesity Therapeutics Consumption and Market Share by Application (2014-2021)
7.2 Global Anti-Obesity Therapeutics Consumption Growth Rate by Application (2014-2021)
7.3 Market Drivers and Opportunities
7.3.1 Potential Applications
7.3.2 Emerging Markets/Countries

Chapter 8 Anti-Obesity Therapeutics Manufacturing Cost Analysis
8.1 Anti-Obesity Therapeutics Key Raw Materials Analysis
8.1.1 Key Raw Materials
8.1.2 Price Trend of Key Raw Materials
8.1.3 Key Suppliers of Raw Materials
8.1.4 Market Concentration Rate of Raw Materials
8.2 Proportion of Manufacturing Cost Structure
8.2.1 Raw Materials
8.2.2 Labor Cost
8.2.3 Manufacturing Expenses
8.3 Manufacturing Process Analysis of Anti-Obesity Therapeutics

Chapter 9 Industrial Chain, Sourcing Strategy and Downstream Buyers
9.1 Anti-Obesity Therapeutics Industrial Chain Analysis
9.2 Upstream Raw Materials Sourcing
9.3 Raw Materials Sources of Anti-Obesity Therapeutics Major Manufacturers in 2020
9.4 Downstream Buyers

Chapter 10 Marketing Strategy Analysis, Distributors/Traders
10.1 Marketing Channel
10.1.1 Direct Marketing
10.1.2 Indirect Marketing
10.1.3 Marketing Channel Development Trend
10.2 Market Positioning
10.2.1 Pricing Strategy
10.2.2 Brand Strategy
10.2.3 Target Client
10.3 Distributors/Traders List

Chapter 11 Market Effect Factors Analysis
11.1 Technology Progress/Risk
11.1.1 Substitutes Threat
11.1.2 Technology Progress in Related Industry
11.2 Consumer Needs/Customer Preference Change
11.3 Economic/Political Environmental Change

Chapter 12 Global Anti-Obesity Therapeutics Market Forecast (2021-2028)
12.1 Global Anti-Obesity Therapeutics Production, Revenue Forecast (2021-2028)
12.2 Global Anti-Obesity Therapeutics Production, Consumption Forecast by Regions (2021-2028)
12.3 Global Anti-Obesity Therapeutics Production Forecast by Type (2021-2028)
12.4 Global Anti-Obesity Therapeutics Consumption Forecast by Application (2021-2028)
12.5 Anti-Obesity Therapeutics Price Forecast (2021-2028)

Chapter 13 Appendix

Request For Methodology

To receive a sample copy of this report, please complete the form below

Kindly share your specific requirement (if any)

Request For List Of Tables

To receive a sample copy of this report, please complete the form below

Kindly share your specific requirement (if any)

FAQ

At what rate will the Anti-Obesity Therapeutics Market grow?

The Global Anti-Obesity Therapeutics Market size is estimated to reach $10.1 Billion by 2026 growing at a CAGR of 16.8% over the forecast period of 2021-2026.

What is Anti-Obesity Therapeutics?

Anti-obesity therapies are medications that help people lose or maintain their weight. These drugs affect one of the body's most basic functions, weight management, by affecting appetite or calorie absorption. Dieting and physical activity remain the primary therapeutic strategies for overweight and obese people.

What are the key factors driving the Anti-Obesity Therapeutics Market?

Increasing number of Bariatric Surgery drives the Anti-Obesity Therapeutics market demand. Previously, bariatric surgery/weight loss surgery was thought to be the final resort for weight loss when diets, exercise, and other medically advised regimens had failed. Bariatric operations, on the other hand, have become less unpleasant for patients as a result of technical developments.

What are the top companies in the Anti-Obesity Therapeutics Market?

Bristol-Myers Squibb, Eisai Company, GlaxoSmithKline plc, Novo Nordisk, Alizyme, Boehringer Ingelheim GmbH, Pfizer, Takeda Pharmaceutical, Rhythm Pharmaceuticals, Shionogi USA, Vivus, Zafgen and Norgine Pharmaceuticals Ltd. among others.

In which Region the market is growing?

North America dominated the Global Anti-Obesity Therapeutics Market with share of 37.9% in 2020. This is owing to increasing obesity population in United States driving the demand in North America. Furthermore, increasing dominance of anti-obesity treatment with high usage of obesity management products led to major share of Anti-Obesity Therapeutics Market in North America.

Choose License Type

Single User

US$ 4700

Multi User

US$ 7200

Corporate User

US$ 9000

Personalize this Research

  • Market Size and Share from 2016 - 2027
  • Expected Market Growth Until 2027
  • COVID-19 Impact assessment on the market
  • Market Dynamics and Impact Analysis
  • Segment and region that will drive or lead the market growth and why
  • Industry activity comprising Mergers, Acquisitions, Expansion, etc.
  • Comprehensive Mapping of the Competitive Landscape
  • In-depth analysis of key sustainability strategies adopted by market players
  • Global and regional market trends – Current and Future
  • Value Chain Analysis
  • Porters Five Forces Analysis
  • Historical and Current Product Pricing
  • Country Cross-Segment Analysis
  • Company Profiling
  • Player Comparison Matrix

Life Science Clients

Anti-Obesity Therapeutics Market Size, Share & Tre...

RD Code : HP21